Clinical Trial Detail

NCT ID NCT03363893
Title Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Carrick Therapeutics Limited
Indications

Her2-receptor negative breast cancer

lung small cell carcinoma

triple-receptor negative breast cancer

prostate cancer

Advanced Solid Tumor

ovarian cancer

Therapies

ICEC0942

Fulvestrant + ICEC0942

Age Groups: senior adult

No variant requirements are available.